Literature DB >> 9723437

Chemical modification of rapamycin: the discovery of SDZ RAD.

R Sedrani1, S Cottens, J Kallen, W Schuler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723437     DOI: 10.1016/s0041-1345(98)00587-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  29 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  Everolimus.

Authors:  Michael B Atkins; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

Review 3.  Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.

Authors:  David Marlevi; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2021-05-18       Impact factor: 24.094

4.  Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.

Authors:  Mei Liu; Yong Lin; Xian-Chao Zhang; Yu-Huan Tan; Yue-Liang Yao; Juan Tan; Xia Zhang; You-Hong Cui; Xindong Liu; Yan Wang; Xiu-Wu Bian
Journal:  Lab Invest       Date:  2017-07-31       Impact factor: 5.662

5.  Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.

Authors:  Andreas Günther; Philipp Baumann; Renate Burger; Christian Kellner; Wolfram Klapper; Ralf Schmidmaier; Martin Gramatzki
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

6.  Metastatic Renal Cancer: What Role for Everolimus?

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Clin Med Rev Oncol       Date:  2010-02-18

Review 7.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

Review 8.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

9.  Everolimus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.